ZURICH (Reuters) -Swiss medical technology company Ypsomed said on Friday it will establish its first manufacturing facility in the United States with an initial $200 million investment in the town of
Ypsomed to Launch First U.S. Manufacturing Plant with $200 Million Investment
Ypsomed's Expansion into the U.S.
ZURICH (Reuters) -Swiss medical technology company Ypsomed said on Friday it will establish its first manufacturing facility in the United States with an initial $200 million investment in the town of Holly Springs, North Carolina.
Job Creation and Future Plans
Ypsomed, a maker of self-injection systems, said it plans to create about 100 new jobs and wants to roughly double that number in the coming years as demand rises. The plant is due to begin supplying the U.S. market from the end of 2027.
Challenges from Trade Policies
The investment comes as Swiss companies grapple with the challenges posed by the U.S. government's trade policies, which have imposed 39% tariffs on Switzerland.
Global Manufacturing Strategy
Earlier this year, Ypsomed opened its first manufacturing plant in China. The firm is also expanding its operations in the northeastern German city of Schwerin, where it is investing several hundred million Swiss francs.
Ypsomed is also increasing domestic production capacity, including a 200 million franc ($248 million) outlay at its facility in Solothurn in northwest Switzerland.
($1 = 0.8056 Swiss francs)
(Reporting by Dave Graham, editing by Thomas Seythal)
